Bay Area Biotech Roundtable: What Does It Take To Excel In The Global Marketplace? (Part 3 of 3)
This article was originally published in The Pink Sheet Daily
Avigen, Genomic Health, Nuvelo, Poniard and Rigel execs sit down with "The Pink Sheet" DAILY to discuss Wall Street’s pipeline expectations, reducing R&D risk, and the California stem cell initiative.
You may also be interested in...
Avigen, Genomic Health, Nuvelo, Poniard and Rigel execs sit down with "The Pink Sheet" DAILY to discuss Asia, pharmacogenomics, and FDA's position on biomarkers.
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.